Cetera Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Cetera Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-1,597	Closed	-$294K	–	731
2014 Q4	$294K	Buy	1,597 +49	+3%	+$9.08K	0.03%	485
2014 Q3	$257K	Buy	+1,548	New	+$254K	0.02%	488
2014 Q2	–	Sell	-1,413	Closed	-$214K	–	636
2014 Q1	$214K	Buy	+1,413	New	+$225K	0.03%	474

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Cetera Advisors's ALXN Position: Q1 2015 in Review

Cetera Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2015, closing a stake of 1,597 shares — an estimated $294K sold.

Cetera Advisors first reported a position in ALXN in Q1 2014 and held it in 3 quarters. The position peaked at $294K in Q4 2014. 566 funds tracked by Wall St. Rank hold ALXN as of Q1 2015.

Cetera Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Cetera Advisors sold 1,597 Alexion Pharmaceuticals shares in Q1 2015, an estimated $294K.
Cetera Advisors first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 3 quarters.
Cetera Advisors's Alexion Pharmaceuticals position peaked at $294K in Q4 2014.
566 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2015.

Based on Cetera Advisors's 13F filing for Q1 2015, filed 15 May 2015.